4564.T OncoTherapy Science JPX pre-market most active: JPY 22.00, vol 38.53M catalyst ahead
Pre-market activity puts OncoTherapy Science, Inc. (4564.T stock) among JPX’s most active names on 22 Jan 2026. The share price is JPY 22.00 with 38,531,800.00 shares traded and intraday range JPY 21.00–22.00. Higher volume follows renewed interest in the clinical pipeline and an upcoming earnings announcement on 30 Jan 2026. Traders should note the mix of stretched technicals and thin float dynamics that can amplify moves in the short term.
Pre-market volume and price action for 4564.T stock
OncoTherapy Science (4564.T stock) is trading at JPY 22.00 in JPX pre-market on 22 Jan 2026 with reported volume at 38,531,800.00. The stock opened at JPY 21.00 and is at the upper end of its intraday band JPY 21.00–22.00. High relative volume versus the 50-day average (price avg 50: JPY 21.54) marks it as most active for early session scalps and momentum strategies.
Fundamentals and valuation of 4564.T stock
OncoTherapy Science shows a market cap of JPY 7,560,158,716.00, EPS of -2.83 and a trailing PE of -7.77, reflecting continued R&D losses. Key ratios show price-to-sales 7.90 and price-to-book 4.26, above Healthcare peers where price-to-sales averages about 1.90. The company carries strong liquidity (current ratio 8.63) and cash per share JPY 5.26, which cushions near-term funding risk but keeps valuation elevated relative to sector medians.
Technical picture and trading signals for 4564.T stock
Technicals are mixed: RSI sits at 68.81, CCI at 277.90 and MACD histogram is positive, signaling short-term upside momentum. Bollinger bands place the upper band at JPY 23.10, suggesting limited immediate room before volatility spikes. Average volume is large; OBV remains negative which warns larger holders may not yet confirm the move. Traders should watch a break above JPY 23.10 or a rejection back to JPY 19.00 for trade triggers.
Clinical pipeline news and catalysts driving 4564.T stock
OncoTherapy’s pipeline—peptide vaccines S-588410 (Phase III esophageal cancer) and S-588210 (Phase II bladder cancer), plus small molecules OTS167 and OTS964—remains the primary fundamental catalyst. Recent Reuters company profile highlights the firm’s industrial-academic partnerships and licensing model source. Positive trial readouts or licensing deals typically lift the shares; conversely, delays or negative data can compress valuation quickly.
Meyka AI grade, analyst context and 4564.T stock forecast
Meyka AI rates 4564.T with a score of 65.41 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of JPY 28.51 and a yearly price of JPY 18.22. The monthly projection implies an upside of +29.59% from JPY 22.00, while the yearly projection implies a downside of -17.27%. Forecasts are model-based projections and not guarantees.
Risk profile and trading considerations for 4564.T stock
Primary risks include binary clinical outcomes, small free-float volatility and concentrated biotech flows. Financials show negative margins (net profit margin -86.26%) and negative ROE (-77.04%), underscoring development-stage risk. For active traders the combination of high intraday volume and stretched momentum metrics increases short-term reward and tail risk; position sizing and stop discipline are essential.
Final Thoughts
OncoTherapy Science (4564.T stock) is one of JPX’s most active pre-market movers on 22 Jan 2026, trading at JPY 22.00 with 38,531,800.00 shares changing hands. The stock blends strong liquidity and a deep clinical pipeline with stretched valuation metrics (price-to-sales 7.90, price-to-book 4.26) and negative earnings (EPS -2.83). Technical indicators show momentum but also overbought readings, so short-term traders must weigh the potential +29.59% monthly upside (Meyka AI monthly JPY 28.51) against a modelled 12-month downside of -17.27% (Meyka AI yearly JPY 18.22). Meyka AI rates 4564.T with a score of 65.41 out of 100 (Grade B, HOLD), reflecting mixed fundamentals and sector context. Monitor upcoming earnings on 30 Jan 2026 and any trial updates for directional bias. These model forecasts and the Meyka grade are informational and not investment advice.
FAQs
What is driving the pre-market volume in 4564.T stock?
Pre-market interest in 4564.T stock is driven by its clinical pipeline updates and the upcoming earnings announcement on 30 Jan 2026, combined with elevated intraday volume of 38,531,800.00 that attracts momentum traders.
What are the key valuation metrics for 4564.T stock?
Key metrics: market cap JPY 7,560,158,716.00, EPS -2.83, price-to-sales 7.90 and price-to-book 4.26. These show elevated valuation versus Healthcare peers and reflect development-stage losses for 4564.T stock.
What price targets does Meyka AI give for 4564.T stock?
Meyka AI’s forecast model projects a monthly target of JPY 28.51 (+29.59% vs JPY 22.00) and a yearly target of JPY 18.22 (-17.27% vs JPY 22.00). Forecasts are model-based projections and not guarantees.
How does Meyka AI rate 4564.T stock?
Meyka AI rates 4564.T with a score of 65.41 out of 100 (Grade B, HOLD). The grade considers benchmark and sector comparisons, financial growth, key metrics and analyst context.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
